Table 1.
Demographics and baseline characteristics of patients included in the meta-analysis according to study and treatment group.
| Authors | Study design | Sample size T/C | Age T | Intervention T | Control C | Duration | % of male |
|---|---|---|---|---|---|---|---|
| Hougaard (10) | RCT | 43/44 | 55.3 ± 11.0 | EZ (10) + AT (80) | PL (10) + AT (80) | 12 months | T (90.7) C (81.8) |
| Jung (11) | RCT | 34/36 | 60.9 ± 10.9 | EZ (10) + SI (40) | PR (20) | 03 months | T (79.4) C (75) |
| Kovarnik (12) | RCT | 42/47 | 63.5 ± 9.3 | EZ (10) + AT (80) | AT (10) | 12 months | T (78.6) C (66) |
| Brohet et al. (13) | RCT | 208/210 | 63.6 ± 11.1 | EZE 10 mg QD + SIM 10/20 mg QD | SIM 10/20 mg QD | 6 weeks | T (69.7) C (75.2) |
| Cannon et al. (14) | RCT | 9,067/9,077 | 63.6 ± 9.7 | EZE 10 mg QD + SIM 40–80 mg QD | IM 40–80 mg QD | 6 years | T (75.5) C (75.9) |
| Hibi et al. (15) | RCT | 50/53 | 63 ± 10.0 | EZE 10 mg QD + PITA 2 mg QD | PITA 2 mg QD | 10 months | T (82) C (77) |
| Joshi et al. (16) | RCT | 40/40 | 60.3 ± 9.8 | EZE 10 mg QD + ROSU 10 mg QD | ROSU 10 mg QD | 24 weeks | T (55) C (62.5) |
| Masuda et al. (17) | RCT | 21/19 | 64.0 ± 7.9 | EZE 10 mg QD + ROSU 5 mg QD | ROSU 5 mg QD | 6 months | T (90.5) C (84.2) |
| Ran et al. (18) | RCT | 42/42 | 60.4 ± 8.2 | EZE 10 mg QD + ROSU 10 mg QD | ROSU 10 mg QD | 10 weeks | T (76.2) C (73.8) |
| Ren et al. (19) | RCT | 55/58 | 57.3 ± 1.5 | EZE 10 mg QD + ROSU 10 mg QD | ROSU 10 mg QD | 12 months | T (87.3) C (79.3) |
| Ueda et al. (20) | RCT | 54/54 | 71 ± 8.0 | EZE 10 mg QD + ATOR 10–20 mg QD | ATOR 10–20 mg QD | 9 months | T (76) C (81) |
| Wang et al. (21) | RCT | 51/49 | 58 ± 10.0 | EZE 10 mg QD + ATOR 20 mg QD | ATOR 20 mg QD | 12 months | T (60) C (61) |
| Wang et al. (22) | RCT | 50/48 | 63 ± 10.0 | EZE 10 mg QD + ROSU 10 mg QD | ROSU 10 mg QD | 12 months | T (72) C (73) |
| West et al. (23) | RCT | 18/33 | 62 ± 8.0 | EZE 10 mg QD + SIM 40 mg QD | EZE 10 mg QD | 2 years | T (56) C (48) |
| Zou (24) | RCT | 40/40 | 69.3 ± 5.8 | EZE 10 mg QD + ATOR 10 mg QD | ATOR 10 mg QD | 12 months | T ( |
| El-Tamalawy et al. (25) | RCT | 33/32 | 61 ± 7.1 | EZE 10 mg/day + ATOR 40 mg daily | ATOR 80 mg daily | 3 months | T (55) C (70) |
| Klassen et al. (26) | RCT | 10/10 | 62 (59–64) | EZE 10 mg QD + ROSU 20 mg QD or SIM 40 mg | ROSU 20 mg QD | 1 month | T (80) C (70) |
| Oh et al. (27) | RCT | 18/19 | 56.3 ± 7.1 | ATO10 mg + EZE10 mg | ATO 40 mg | 12 months | T (72) C (79) |
| Pinto et al. (28) | RCT | 50/51 | 59 (52–65) | EZE 10mg + SIM 40 mg | ROSU 20 mg | 1 month | T (76) C (72) |
| Blom et al. (29) | RCT | 63/73 | 55.9 ± 9.0 | EZE 10 mg + ATOR 80 mg | ATOR 80 mg | 1–2 months | T (52.4) C (45.2) |
T, treatment group; C, control group; EZ, ezetimibe; ATOR, atorvastatin; SIM, simvastatin.